Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
z7eP5RdyGCz9vXA9